Report Categories
View AllRecent Articles
View All
GBAB Guggenheim reports Q1 2026 earnings with 14 revenue growth but shares retreat 063 amid cautious investor sentiment
What Neumora Therapeutics NMRA disclosed about crisis preparedness NMRA Neumora Therapeutics Q4 2025 Earnings EPS Miss Zero Revenue
BioLife BLFS smashes Q1 estimates with 96 EPS surprise driving 63 stock jump
Dow Inc DOW Secures Zacks Bull of the Day Designation Amid Unprecedented Petrochemical Supply Tailwinds